Asparaginase Escherichia coli

BNP Paribas Financial Markets reduced its stake in Ligand Pharmaceuticals by 27.6% during Q3. Several investors modified their holdings, with Woodstock Corp, Creative Planning, and Mirae Asset Global Investments increasing their positions. Insiders sold shares worth $2.27 million in the last quarter. LGND stock opened at $116.91, with a consensus rating of 'Buy' and an average target price of $145.33. Ligand Pharmaceuticals develops and licenses biopharmaceutical assets globally.

Thrivent Financial reduced its stake in Ligand Pharmaceuticals by 1.6% in Q2. Other hedge funds also adjusted their positions, with Vanguard Group, Dimensional Fund Advisors, Chicago Capital, Rice Hall James, and William Blair Investment Management increasing their holdings. Wall Street analysts forecast growth, with a consensus 'Moderate Buy' rating and an average target price of $131.80. Ligand Pharmaceuticals' stock rose 2.5% to $104.78, with a market cap of $1.89 billion. The company reported quarterly earnings of $1.40 EPS, beating estimates by $0.34, and revenue of $41.50 million, up 57.2% YoY. Insiders sold 51,613 shares over the last 90 days, while CEO Todd C. Davis bought 2,500 shares at $97.39 each.

Jazz Pharmaceuticals (JAZZ) is a global biopharmaceutical company focusing on sleep, hematology/oncology, and pain, with notable products like Xyrem, Xywav, Zepzelca, Rylaze, and Epidiolex. In 2023, it achieved $3.8 billion in revenue, completed a Phase 3 trial for Zepzelca, and advanced zanidatamab development. With $1.6 billion in cash and $5.8 billion in debt, Jazz continues to innovate through R&D and strategic acquisitions, partnering with BeiGene and Life Science Cares.